, Tracking Stock Market Picks
Enter Symbol:
C.r. Bard, Inc. (BCR) [hlAlert]

Mkt Outperform
up 102.98 %

C.r. Bard, Inc. (BCR) rated Mkt Outperform by JMP Securities

Posted on: Wednesday,  Dec 19, 2012  8:25 AM ET by JMP Securities

JMP Securities rated Mkt Outperform C.r. Bard, Inc. (NYSE: BCR) on 12/19/2012. Previously JMP Securities rated Mkt Outperform C.r. Bard, Inc. (NYSE: BCR)
on 04/10/2008., when the stock price was $96.80. Since then, C.r. Bard, Inc. has gained 102.99% as of 01/20/2016's recent price of $196.49.
If you would have followed the previous JMP Securities's recommendation on BCR, you would have gained 102.98% of your investment in 2841 days.

C.R. Bard, Inc. is one of the worldwide leaders in developing, manufacturing, and supplying healthcare products that focus on Vascular, Urology, and Oncology Disease States. In addition, Bard offers a complete line of advanced Surgical Specialty products and services that address needs in hernia repair, performance irrigation, hemostasis, and other areas.

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/19/2012 8:25 AM Buy
as of 12/31/2012
1 Week up  1.21 %
1 Month down  -1.28 %
3 Months down  -6.60 %
1 YTD up  14.31 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/10/2008 8:25 AM Buy
96.80 112.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy